Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease

George H. McCracken, James P. Luby, Stanley A. Plotkin

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Cytosine arabinoside (ARA-C) was used in the treatment of 3 infants with disseminated cytomegalovirus infection. The titer of cytomegalovirus was reduced in vitro 0 to 2 log10 TCID50 with 1.0 μg per millitier, and 2 to 3 log10 TCID50 with 10 and 100 μg per milliliter of ARA-C. The concentration of cytomegalovirus in the urine of the 3 patients was reduced 2 to 3 logs during therapy, but returned to pretreatment titers or higher within several weeks. Transient hematologic and hepatic toxicity were observed during therapy, and ARA-C had no appreciable beneficial effect on the clinical course of the infants.

Original languageEnglish (US)
Pages (from-to)488-495
Number of pages8
JournalThe Journal of Pediatrics
Volume80
Issue number3
DOIs
StatePublished - 1972

Fingerprint

Cytarabine
Cytomegalovirus Infections
Cytomegalovirus
Therapeutics
Urine
Liver

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease. / McCracken, George H.; Luby, James P.; Plotkin, Stanley A.

In: The Journal of Pediatrics, Vol. 80, No. 3, 1972, p. 488-495.

Research output: Contribution to journalArticle

@article{a2b6a9ae0d3b4934b21de8b98db75356,
title = "Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease",
abstract = "Cytosine arabinoside (ARA-C) was used in the treatment of 3 infants with disseminated cytomegalovirus infection. The titer of cytomegalovirus was reduced in vitro 0 to 2 log10 TCID50 with 1.0 μg per millitier, and 2 to 3 log10 TCID50 with 10 and 100 μg per milliliter of ARA-C. The concentration of cytomegalovirus in the urine of the 3 patients was reduced 2 to 3 logs during therapy, but returned to pretreatment titers or higher within several weeks. Transient hematologic and hepatic toxicity were observed during therapy, and ARA-C had no appreciable beneficial effect on the clinical course of the infants.",
author = "McCracken, {George H.} and Luby, {James P.} and Plotkin, {Stanley A.}",
year = "1972",
doi = "10.1016/S0022-3476(72)80515-8",
language = "English (US)",
volume = "80",
pages = "488--495",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease

AU - McCracken, George H.

AU - Luby, James P.

AU - Plotkin, Stanley A.

PY - 1972

Y1 - 1972

N2 - Cytosine arabinoside (ARA-C) was used in the treatment of 3 infants with disseminated cytomegalovirus infection. The titer of cytomegalovirus was reduced in vitro 0 to 2 log10 TCID50 with 1.0 μg per millitier, and 2 to 3 log10 TCID50 with 10 and 100 μg per milliliter of ARA-C. The concentration of cytomegalovirus in the urine of the 3 patients was reduced 2 to 3 logs during therapy, but returned to pretreatment titers or higher within several weeks. Transient hematologic and hepatic toxicity were observed during therapy, and ARA-C had no appreciable beneficial effect on the clinical course of the infants.

AB - Cytosine arabinoside (ARA-C) was used in the treatment of 3 infants with disseminated cytomegalovirus infection. The titer of cytomegalovirus was reduced in vitro 0 to 2 log10 TCID50 with 1.0 μg per millitier, and 2 to 3 log10 TCID50 with 10 and 100 μg per milliliter of ARA-C. The concentration of cytomegalovirus in the urine of the 3 patients was reduced 2 to 3 logs during therapy, but returned to pretreatment titers or higher within several weeks. Transient hematologic and hepatic toxicity were observed during therapy, and ARA-C had no appreciable beneficial effect on the clinical course of the infants.

UR - http://www.scopus.com/inward/record.url?scp=0015309547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015309547&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(72)80515-8

DO - 10.1016/S0022-3476(72)80515-8

M3 - Article

C2 - 4334178

AN - SCOPUS:0015309547

VL - 80

SP - 488

EP - 495

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 3

ER -